This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Adgero Biopharmaceuticals, Inc.
Drug Names(s): rostaporfin, PhotoPoint SnET2, SnET2-PDT, Photrex, REM-001 Therapy
REM-001 is a photosensitizer that generates free-radicals when exposed to light energy. REM-001 Therapy is the collective name for a three-part photodynamic therapy that consists of a laser light source, a light delivery device and the drug REM-001.
At an undisclosed time, Adgero Biopharmaceuticals acquired a portfolio of assets including REM-001 from Miravant Medical Technologies.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: